Browsing by Subject "SARS-2"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Restricted
    Decreased long-term severe acute respiratory syndrome coronavirus 2–specific humoral immunity in liver transplantation recipients 12 months after coronavirus disease 2019
    (Wiley, 2022-01-17) Caballero-Marcos, Aránzazu; Citores, María Jesús; Alonso-Fernández, Roberto; Rodriguez-Perálvarez, Manuel; Valerio, Maricela; Graus Morales, Javier; Cuervas-Mons, Valentín; Cachero, Alba; Loinaz-Segurola, Carmelo; Iñarrairaegui, Mercedes; Castells, Lluís; Pascual, Sonia; Vinaixa-Aunés, Carmen; González-Grande, Rocío; Otero, Alejandra; Tomé, Santiago; Tejedor-Tejada, Javier; Fernández-Yunquera, Ainhoa; González-Diéguez, Luisa; Nogueras-López, Flor; Blanco-Fernández, Gerardo; Díaz-Fontenla, Fernando; Bustamante, Francisco Javier; Romero-Cristóbal, Mario; Martin-Mateos, Rosa; Arias-Millas, Ana; Calatayud, Laura; Marcacuzco-Quinto, Alberto A.; Fernández-Alonso, Victor; Gómez-Gavara, Concepción; Muñoz, Patricia; Bañares, Rafael; Pons Miñano, José Antonio; Salcedo, Magdalena; Medicina
    Long-term humoral immunity and its protective role in liver transplantation (LT) patients have not been elucidated. We performed a prospective multicenter study to assess the persistence of immunoglobulin G (IgG) antibodies in LT recipients 12 months after coronavirus disease 2019 (COVID-19). A total of 65 LT recipients were matched with 65 nontransplanted patients by a propensity score including variables with recognized impact on COVID-19. LT recipients showed a lower prevalence of anti-nucleocapsid (27.7% versus 49.2%; P = 0.02) and anti-spike IgG antibodies (88.2% versus 100.0%; P = 0.02) at 12 months. Lower index values of anti-nucleocapsid IgG antibodies were also observed in transplantation patients 1 year after COVID-19(median, 0.49 [interquartile range, 0.15-1.40] versus 1.36 [interquartile range, 0.53-2.91]; P < 0.001). Vaccinated LT recipients showed higher antibody levels compared with unvaccinated patients (P < 0.001); antibody levels reached after vaccination were comparable to those observed in nontransplanted individuals (P = 0.70). In LT patients, a longer interval since transplantation (odds ratio, 1.10; 95% confidence interval, 1.01-1.20) was independently associated with persistence of anti-nucleocapsid IgG antibodies 1 year after infection. In conclusion, compared with nontransplanted patients, LT recipients show a lower long-term persistence of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, SARS-CoV-2 vaccination after COVID-19 in LT patients achieves a significant increase in antibody levels, comparable to that of nontransplanted patients.